Merck Pushes Discount Zocor; Health Plans Are Wary, But Pfizer Is Concerned

The mixed response to Merck's efforts to reach rebate agreements with health plans to place brand Zocor on the lowest cost-sharing tiers of their formularies suggests it is unlikely such a strategy would be broadly adopted by brand firms going forward